Kornimate/medical-research-clean huggingface dataset:
nad augmentation in diabetes kidney disease

Conditions: Type2diabetes; Diabetic Kidney Disease

Summary: a phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether nmn administration improves dkd, as indicated by a significantly greater reduction in uacr compared with placebo administration. eligible participants will be randomized to receive either 1000 mg nmn or placebo twice daily.

this will be two centers, randomized, double-blind, placebo-controlled, parallel group trial to determine whether βnmn, after its daily oral administration, is associated with a greater reduction in the uacr compared to placebo. the trial will enroll community-dwelling older adults, 60 years or older, with type 2 diabetes mellitus (t2dm) and urine albumin to creatinine excretion ratio \> 100 mg/ g creatinine.

Eligibility criteria:
inclusion criteria: 1. has t2dm, as indicated by any of the following: 1. self-report of diabetes plus the use of a prescribed diabetes medication. 2. icd-10 code for diabetes plus current use of a diabetes medication in the electronic medical record. 3. hba1c \>6.4%; or 2 fasting glucose \> 125 mg/dl 2. fasting morning uacr between 100 and 2,000 mg/g creatinine on two separate days 3. if uacr is \> 300 mg/g creatinine, must be currently using an ace inhibitor or an arb 4. egfr \> 30 ml/ min / 1.73 m2 5. hemoglobin a1c \<9% 6. able to speak english or spanish 7. willing and able to provide written informed consent 8. in addition, female participants must not be pregnant and not planning to become pregnant over the next 6 months exclusion criteria: 1. fasting morning uacr \> 2,000 mg/ g creatinine 2. other laboratory abnormalities: 1. has ast or alt \> 3 times the upper limit of normal 2. creatinine \> 2.5 mg/dl 3. hematocrit \< 0.34 or 0.50 l/l 3. a major adverse cardiovascular event in preceding 3 months 4. participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter 5. hypoglycemia unawareness or other medical conditions which could jeopardize participant's safety. 6. history of alcohol or substance use disorder or dependence (dsm 5 criteria) within the last 2 years. 7. major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures. 8. bmi \> 42.5 kg/ m2

Keywords: diabetes type 2 diabetes kidney disease
a study of dual-task exercise training to prevent falls among older adults with mild cognitive impairment

Conditions: Mild Cognitive Impairment; Accidental Falls; Aging

Summary: to determine the efficacy of a dual-task tai ji quan training therapy in reducing the incidence of falls in older adults with mild cognitive impairment.

the primary aim of the study is to determine the comparative efficacy of two tai ji quan interventions (dual-task tai ji quan, standard tai ji quan), relative to a stretching exercise control, in reducing the incidence of falls among community-dwelling older adults with mild cognitive impairment.

Eligibility criteria:
inclusion criteria: * being 65 years and older * having complaint of memory loss * scoring ≤0.5 on clinical dementia scale * having had 1 or more falls in the preceding 12 months or scoring ≥12 seconds on the timed up and go test exclusion criteria: * scoring \<24 on the mini-mental state examination * being able to ambulate independently for household distances * having medical clearance * having participated in any regular and structured tai ji quan-based exercise programs (≥2 times weekly) in the preceding 6 months * having a progressive neuromuscular disorder such as parkinson's disease or multiple sclerosis * being unwilling to be randomized

Keywords: falls exercise dual tasking
vonoprazan evaluation compared to standard triple therapy in helicobacter pylori eradication

Conditions: Helicobacter Pylori Infection

Summary: helicobacter pylori (h pylori) infection is associated with functional dyspepsia, peptic ulcer disease, atrophy and gastric cancer. the bacterium has been classified as grade i carcinogen by the who in 1994(1). based on the clinical and microbiological data it is now well known to be the strongest risk factor for developing intestinal type and diffuse type of adenocarcinoma(2-4). while testing and treating asymptomatic persons is a grey area, it is now recommended to rule out h. pylori in un-investigated dyspepsia patients (5-7), and if detected, it must be treated. however, worldwide and especially in the asian countries, we face a widespread problem of antibiotic resistance(8,9). regimens are typically selected based on the varying regional clarithromycin resistance(6,9). there is a need for an efficient and reliable empirical therapy that can be universal, has maximal eradication rates irrespective of resistance patterns, has good compliance and minimal adverse events without the emergence of superbugs. we also need a reliable rescue therapy for h. pylori eradication failure.


Eligibility criteria:
inclusion criteria: * adult (18 years - 80 years) * patient visiting clinic with dyspepsia, gerd, or non-bleeding peptic ulcer * 13c-urea breath test (ubt) positive/ rapid urease test positive (rut) on endoscopic biopsy * off ppis for 2 weeks exclusion criteria: * penicillin allergy * recent use of antibiotics in the past 1 month * previous h. pylori therapy * intestinal metaplasia, gastric cancer, bleeding peptic ulcer * patient who is unable to understand study protocol or not consenting * pregnancy, lactation * patient on anticoagulation, nsaids * patient using drugs with interactions with vonoprazan, amoxicillin, clarithromycin or ppis * cirrhosis, chronic kidney disease, chronic lung disease
virtual reality in hand peripheral nerve injuries effectiveness of based movement therapy

Conditions: Peripheral Nerve Injury, Virtual Reality, Rehabilitation

Summary: the aim of this study is to investigate the effectiveness of virtual reality-based motion therapy in peripheral nerve injuries in the hand.


Eligibility criteria:
inclusion criteria: * ıt was operated in the early period with the diagnosis of peripheral nerve injury in the postoperative hand. * clinical impression was made. * out patient with median, ulnar, and radial nerve repair. * completed the 6th postoperative week. exclusion criteria: * those who have communication problems and users * with the musculoskeletal system, the additional passage, rheumatological, etc., where they are located. those with the disease - patients with multiple traumas
establishment, verification and clinical application of chinese version of surgical risk assessment system

Conditions: Risk Assessment; Risk Factors; Machine Learning; Artificial Intelligence; Postoperative Complications; Operative Surgical Procedure

Summary: the goal of this observational study is to establish and verify the chinese version of surgical risk assessment system and explore its clinical application. the main questions it aims to answer are: the process of establishing a chinese version of surgical risk assessment system; what is the accuracy of the system; how can the system be used in clinic; how does this system compare with other systems (such as nsqip). participants will comprehensively collect the general information, examination and pathological information of the patients, using machine learning and artificial intelligence methods for data processing. finally, the chinese version of the surgical risk assessment system will be established. after the system is established, investigators will evaluate the accuracy of the system and compare it with other related systems.

the research process is as follows: 1. determine the collection index and the complications to be evaluated, and retrospectively collect the preoperative clinical data (including preoperative medical records, examination and examination results) of patients with postoperative complications of gastric and colorectal cancer in our hospital in the past ten years. preliminary construction of surgical risk assessment system (gastrointestinal surgery) 2. retrospective or prospective collection of gastric cancer and colorectal surgery cases (not included in the system) 3. the occurrence of postoperative complications was observed until 1 month after discharge. compare the evaluation results of the system with the actual situation and feedback to further improve the system. 4. the same batch of patient data can be input into nsqip to re-evaluate and predict the occurrence of patient complications, and then compare the results of the two systems. 5. the incidence of postoperative complications (number of cases and accuracy) of the two groups were counted respectively, and the accuracy and practicability of the evaluation of the two systems were compared to further improve the system.

Eligibility criteria:
inclusion criteria: * preoperative colonoscopy and biopsy confirmed gastric and colorectal cancer. * laparotomy or laparoscopic radical resection of gastric or colorectal cancer. * no postoperative complications such as pneumonia, venous thrombosis, cardiovascular and cerebrovascular accidents occurred before operation. * there was no serious organ dysfunction before operation. * complete auxiliary examination and the availability of examination and examination data were carried out before operation. exclusion criteria: * complicated with malignant tumors of other organs. * unresectable tumors. * distant metastasis. * severe organ system dysfunction before operation. * patients with non-operative treatment.
citrus extract, sleep and mental wellbeing

Conditions: Sleep Disturbance

Summary: this is a randomized, double-blind, placebo-controlled, cross-over trial investigating the effects of daily administration of citrus extract on sleep and mental wellbeing.

based on epidemiological data, a substantial number of people report to have sleeping problems. this is of major concern, as poor sleep quality has been associated with impaired mental and physical health. several pre-clinical studies have shown promising results, but evidence from human studies is still limited. therefore, the aim of the present study is to investigate the effect of a citrus extract on sleep and mental wellbeing in healthy subjects with (minor) sleep disturbance.

Eligibility criteria:
inclusion criteria: * healthy individuals with (minor) sleep disturbance * age 40-70 years * bmi 18.5 - 30 kg/m2 * willingness to give up being a blood donor from 4 weeks before the start of the study, during the study and for 4 weeks after completion of the study exclusion criteria: * excessive caffeine use * major psychiatric/mental health disorders . * chronic sleep disorders * severe sleep disturbance for more than 1 year * other clear causes for poor sleep quality or mental wellbeing * use of medication or supplements that can affect outcomes * nonpharmacological treatment for sleep disorders * flight from a time-zone with \>3 h difference ≤1 week before an intervention period * administration of investigational drugs or participation in any scientific intervention study which may interfere with this study * use of pre-, pro- or synbiotics within 1 month prior to the start of the study * reported weight loss or weight gain of \>3 kg in the month prior to pre-study screening * smoking * abuse of products * known allergy to citruses * known pregnancy or lactation
a study of mrna-1011.1, mrna-1011.2, and mrna-1012.1 candidate seasonal influenza vaccines in healthy adults

Conditions: Seasonal Influenza

Summary: the purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mrna-1011.1, mrna-1011.2, and mrna-1012.1) compared with influenza vaccine candidate mrna-1010 controls in healthy adult participants.


Eligibility criteria:
key inclusion criteria: * body mass index of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the screening visit. * for female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to day 1, agreement to continue adequate contraception through 3 months following vaccine administration, and not currently breastfeeding. key exclusion criteria: * participant is acutely ill or febrile (temperature ≥38.0 degrees celsius \[°c\]/100.4 degrees fahrenheit \[°f\]) 72 hours prior to or at the screening visit or day 1. * any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. * participant has received systemic immunosuppressants for \>14 days in total within 180 days prior to the randomization visit (for glucocorticosteroids ≥10 milligrams \[mg\]/day of prednisone equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study (including intra-articular steroid injections). inhaled, nasal, and topical steroids are allowed. * participant has received or plans to receive any licensed or authorized vaccine, including covid-19 vaccines, ≤28 days prior to the study injection (day 1) or plans to receive a licensed or authorized vaccine within 28 days after the study injection. * participant has received a seasonal influenza vaccine or any other influenza vaccine within 180 days prior to the randomization visit. * participant tested positive for influenza by local health authority-approved testing methods within 180 days prior to the randomization visit. * participant has had close contact to someone with or been diagnosed themselves with respiratory syncytial virus or sars-cov-2 infection as defined by the centers for disease control and prevention (cdc) in the past 10 days prior to the randomization visit. * participant has donated ≥450 milliliters (ml) of blood products within 28 days prior to the randomization visit or plans to donate blood products during the study. note: other inclusion/exclusion criteria may apply.

Keywords: influenza vaccine mrna-1010 mrna-1011.1 mrna-1011.2 mrna-1012.1 moderna
exercise and ric and tcd

Conditions: Stroke, Acute

Summary: the first week after a stroke is a particularly important time, as improving blood flow may limit secondary ischaemic damage to the brain and help reduce the overall burden neurological injury and future disability. small studies in patients with stroke have shown that moderate aerobic exercise increases blood flow to the brain, however, no studies have evaluated the safety of aerobic exercise within the first week after stroke, nor whether it results in changes to cerebral blood flow. remote ischaemic conditioning (ric) is when ischaemia is induced to a limb for short periods of time by inflating pressure cuffs around arms or legs to above systolic pressures (mmhg). this procedure is performed for periods that avoid physical injury to the limbs, but induce neurohormonal, systemic or vascular changes in the body. these changes often result in improved blood supply to various areas of the body. the use of ric in the acute period after stroke is currently being investigated in a number of large randomised controlled trials e.g. recast, resist, however, our understanding of how ric actually works is incomplete. importantly, there is scarce data on the acute effects of ric on cerebral blood flow (cbf), a potentially pivotal mechanism behind its effects. we propose an exploratory study to evaluate whether it is feasible, acceptable and safe to undertake low and moderate intensity aerobic exercise or remote ischaemic conditioning (ric) in patients during the acute period after stroke, and whether either of these interventions result in changes to cerebral blood flow velocity (cbfv) in the major cerebral arteries. we will compare any changes to those in a cohort of healthy volunteers.


Eligibility criteria:
inclusion criteria: * adult (age \> 18) patients who have suffered acute ischaemic stroke between 2-7 days previously, or healthy adult (\>18 years). * ability to provide written informed consent * ability to mobilise lower body limbs (at least one leg) * ability to comply with study procedures in the opinion of the treating physician. exclusion criteria: * haemorrhagic stroke * ischaemic stroke \ 10 days * disability preventing lower extremity cycling * new york heart failure classification stage iii/iv * history of ischaemic stroke * current diagnosis of cancer * resting blood pressure \> 180 / 100 mmhg * clinically unstable * history or presence of significant peripheral vascular disease in the upper limbs. * history or presence of complex neuropathic pains or peripheral neuropathy in the arms. * presence of lymphoedema in the arms. * presence of skin ulceration to the arms. * uncontrolled arrhythmia, hypertension, diabetes or angina. * acute deep vein thrombosis, pulmonary embolism or pulmonary infection.
vitamin d and sleep disorders in pregnancy

Conditions: Sleep Disorder; Pregnancy Related; Vitamin D Deficiency

Summary: lack of sleep and poor sleep quality in pregnant women are associated with maternal depression and cognitive-sensual irregularities. these irregularities were reported worsening women's life quality and even increasing suicide ideation. it is also associated with obstetrical complications such as fetal growth deficiency, preterm birth, prolonged labor, preeclampsia and increased abdominal delivery frequency.vitamin d also may affect the sleep indirectly through the cases with nonspecific pains. it was reported that vitamin d levels are correlated with sleep disorders such as obstructive sleep apnea and restless legs syndrome. the primary purpose of this study is to examine sleep disorders and vitamin d levels in pregnant women, and also, secondarily, vitamin d - anxiety and sleep disorders - anxiety relations were assessed.


Eligibility criteria:
inclusion criteria: * singletone pregnant women * second and third trimester pregnant women exclusion criteria: * psychiatric disorder * sleep disorder

Keywords: anxiety pregnancy, sleep wake disorders vitamin d
subcutaneous ig in allogeneic stem cell transplant recipients

Conditions: Hypogammaglobulinemia

Summary: tolerability of home subcutaneous immunoglobulin (scig) for replacement therapy for hypogammaglobulinemia in allogeneic hct patients. a financial analysis comparing the cost of scig with intravenous immunoglobulin (ivig) will also be performed.

the purpose of the study is to determine whether home subcutaneous immunoglobulin (scig) is tolerated as replacement therapy for hypogammaglobulinemia in patients that have undergone allogeneic hematopoietic cell transplantation (allohct). secondary objective is to perform a financial analysis comparing the cost of scig with intravenous immunoglobulin (ivig). the study hypothesis is that home based scig treatment is applicable and tolerated well for replacement treatment in allohct patients. this will be examined in two sets of patients recruited: a) patients already on ivig replacement therapy and b) newly diagnosed patients with hypogammaglobulinemia. economic analysis will be performed by comparing the cost with an equal number of patients retrospectively determined to have undergone treatment with ivig.

Eligibility criteria:
inclusion criteria: * age over 18 years * patients at least 100 days post allogeneic hematopoietic cell transplantation for any benign or malignant hematological disease, from a related or unrelated donor * patients who are already established on regular ivig * patients eligible for immunoglobulin replacement with an igg \<7mg/l, or normal igg total but igg2 or igg4 below normal * patients with igg =\>7g/l but with at least 2 prior episodes of bacterial infection (proven or suspected eg. sinusitis diagnosed on ct) * no other medical condition which would preclude treatment with immunoglobulin * willing to participate and sign informed consent exclusion criteria: * previous serious adverse reaction from ivig or products from hizentra (polysorbate) * other serious medical or psychiatric disorders which may interfere with the patient's ability to participate in the study, or interfere with study assessment (e.g. advanced congestive heart failure, severe liver disease, renal failure, disease relapse or secondary malignancy, schizophrenia, paranoid psychosis)

Keywords: hypogammaglobulinemia allogeneic hematopoietic cell transplantation
telemedicine-based virtual reality clinic for the treatment of phobias

Conditions: Arachnophobia; Cynophobia; Ophidiophobia

Summary: the purpose of this study is to assess the feasibility of conducting a randomized controlled efficacy trial comparing the delivery of exposure therapy via a telemedicine-based virtual reality clinic (doxy.me vr) vs. standard telemental health (tmh) to adults with intense fear of dogs, snakes, and/or spiders. the secondary purpose is to preliminarily examine the efficacy of using doxy.me vr vs. tmh in reducing phobia severity.

this study aims to assess the feasibility of conducting a randomized controlled efficacy trial comparing the delivery of exposure therapy via a telemedicine-based virtual reality clinic (doxy.me vr) vs. standard telemental health (tmh) to adults with intense fear of dogs, snakes, and/or spiders. this study will use feasibility randomized controlled efficacy trial design. this single-site trial will include up to 60 adults with self-reported fear of dogs, snakes, and/or spiders who will be randomly assigned via the redcap randomization module using a 1:1 allocation ratio to receive 12 sessions of exposure therapy over the course of 3 months via standard telemental health (tmh; n=15) vs. doxy.me vr (n=15), a telemedicine-based virtual reality clinic.

Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. is an adult ≥ 18 years old 2. has a self-reported fear of dogs, snakes, and/or spiders 3. indicates subthreshold or present specific phobia symptoms as determined by the study therapist via administration of the diagnostic assessment research tool (dart) specific phobia module 4. has access to the internet and a computer or smartphone with video conferencing capabilities 5. will reside in the state of florida for the duration of the study exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. is participating in ongoing mental health therapy from a non-study therapist 2. has had changes to psychotropic medication use within six weeks preceding enrollment in the trial 3. reports active suicidal and/or homicidal intent or plan as determined by the study therapist via administration of the diagnostic assessment research tool (dart) risk assessment module 4. reports active auditory, visual, and/or tactile hallucinations via the diagnostic assessment research tool (dart) psychosis module screening question 5. reports a history of epilepsy or seizures

Keywords: phobia phobias snakes dogs spiders
gemcitabine, oxaliplatin and radiotherapy in treating patients with completely resected pancreatic cancer

Conditions: Pancreatic Neoplasms

Summary: a non-randomized phase ii study to determine the efficacy and safety of the combination of gemcitabine and oxaliplatin followed by gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.


Eligibility criteria:
inclusion criteria: * pathologically confirmed adenocarcinoma of the pancreas * patient have undergone a potentially curative resection * no previous irradiation to the planned field * negative pregnancy test for child bearing women exclusion criteria: * non-adenocarcinoma pancreatic cancer * treatment with any drug within the last 30 days that has not received regulatory approval. * serious systemic disorder * metastatic disease * pregnancy, breast feeding